153 related articles for article (PubMed ID: 18327991)
21. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
22. Treatment of metabolic syndrome.
Wagh A; Stone NJ
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
[TBL] [Abstract][Full Text] [Related]
23. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
24. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
25. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients.
Kinouchi K; Ichihara A; Sakoda M; Kurauchi-Mito A; Murohashi-Bokuda K; Itoh H
Kidney Blood Press Res; 2010; 33(4):304-12. PubMed ID: 20664284
[TBL] [Abstract][Full Text] [Related]
26. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.
Goebel M; Clemenz M; Unger T
Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):615-29. PubMed ID: 17081084
[TBL] [Abstract][Full Text] [Related]
27. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
28. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
29. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
30. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
31. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E
Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028
[TBL] [Abstract][Full Text] [Related]
32. Telmisartan and metabolic syndrome after heart transplantation.
Luknar M; Goncalvesova E; Lesny P; Fabian J
Clin Transplant; 2010; 24(1):36-9. PubMed ID: 19222503
[TBL] [Abstract][Full Text] [Related]
33. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
Kojima M; Ohashi M; Dohi Y; Kimura G
J Hypertens; 2013 Jan; 31(1):186-91. PubMed ID: 23047595
[TBL] [Abstract][Full Text] [Related]
34. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
35. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.
Haffner SM
Am J Med; 2006 May; 119(5 Suppl 1):S3-9. PubMed ID: 16563945
[TBL] [Abstract][Full Text] [Related]
36. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
Hasegawa G; Fukui M; Hosoda H; Asano M; Harusato I; Tanaka M; Shiraishi E; Senmaru T; Sakabe K; Yamasaki M; Kitawaki J; Fujinami A; Ohta M; Obayashi H; Nakamura N
Eur J Pharmacol; 2009 Mar; 605(1-3):164-9. PubMed ID: 19171132
[TBL] [Abstract][Full Text] [Related]
37. The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly.
Formosa V; Bellomo A; Iori A; Gianturco V; D'Ottavio E; Mancinella M; Lo Iacono C; Troisi G; Marigliano V
Arch Gerontol Geriatr; 2009; 49 Suppl 1():95-101. PubMed ID: 19836621
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
Lacourcière Y
Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964
[TBL] [Abstract][Full Text] [Related]
39. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
